



IFW

Attorney Docket No. 57636-8013.US01

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on:

Date: September 29, 2004

By: Susan L Baka  
Susan Baka

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF:

Laus, *et al.*

APPLICATION No.: 10/772,856

FILED: February 4, 2004

FOR: COMPOSITION AND METHOD FOR  
PRODUCING AN IMMUNE RESPONSE  
AGAINST TUMOR-RELATED ANTIGENS

EXAMINER: Unassigned

ART UNIT: 1653

CONF. No: 7281

**Information Disclosure Statement Within Three Months of  
Application Filing or Before First Action – 37 C.F.R. § 1.97(b)**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

1. Timing of Submission

This information disclosure is being filed within three months of the filing date of this application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever occurs last (37 C.F.R. § 1.97(b)). The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. Cited Information

☒ Copies of the following references can be found in parent U.S. Application No. 09/402,845:

- ☒ All cited references
- ☐ References marked by asterisks
- ☐ The following:

3. Effect of Information Disclosure Statement (37 C.F.R. § 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

4. Fee Payment

No fees are believed due because this Information Disclosure Statement is being filed before the mailing date of the first Office Action.

However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2207.

5. Patent Term Adjustment (37 C.F.R. § 1.704(d))

- ☐ The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).

Respectfully submitted,  
Perkins Coie LLP

Date: SEP. 29, 2004

  
\_\_\_\_\_  
Jason J. Schwartz  
Registration No. 43,910

**Correspondence Address:**

Customer No. 22918  
Perkins Coie LLP  
P.O. Box 2168  
Menlo Park, California 94026  
(650) 838-4300



**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
Form PTO-1449 (Modified)  
(Use several sheets if necessary)

**COMPLETE IF KNOWN**

Application Number	10/772,856
Confirmation Number	7281
Filing Date	February 4, 2004
First Named Inventor	Laus, <i>et al.</i>
Group Art Unit	1653
Examiner Name	Unassigned
Attorney Docket No.	57636-8013.US01

Sheet 1 of 2

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		NUMBER	Kind Code (if known)			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Foreign Patent or Application			Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	NUMBER	Kind Code (if known)				


**OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
		Bork, <i>Genome Research</i> <u>10</u> :398-400, (2000).	
		Bowie, <i>et al.</i> , <i>Science</i> <u>247</u> :1306-1310, (1990).	
		Burgess, <i>et al.</i> , <i>J Cell Bio</i> <u>111</u> :2129-2138, (1990).	
		Fong, L., <i>et al.</i> , <i>Proc Amer Assoc Cancer Research 88<sup>th</sup> Annual Meeting</i> 38:356 #2386 (1997).	
		Fong, L., <i>et al.</i> , <i>Journal of Immunology</i> <u>159</u> :3113-3117 (1997).	
		Iype, <i>et al.</i> , <i>Arch Biochem Biophys</i> <u>128</u> (2):434-441, (1968).	
		Johnstone, <i>et al.</i> , <i>IMMUNOCHEMISTRY IN PRACTICE</i> , 2 <sup>nd</sup> Edition, Blackwell Scientific Publications, Oxford, England, pp. 30, (1987).	
		Kuciel, <i>et al.</i> , <i>Biotechnol Apl Biochem</i> <u>10</u> (3):257-272, (1988).	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).

[illegible]